Portfolio Snapshots

We are an international equities manager, and we invest with a truly global outlook.

Here is a snapshot of the current portfolio disposition of our flagship Platinum Trust Funds and their key holdings.

Platinum International Health Care Fund

Platinum International Health Care Fund invests in health care companies from around the world, ranging from those engaged in early exploratory research to those providing health care services directly to consumers.

Established in 2003, the fund now has A$478.1 million under management^ and a track record of achieving 11.3% compound return annually since inception (on 10/11/2003).*

Platinum International Health Care Fund provides exposure to companies engaged in the provision of a wide range of products and services within the global healthcare ecosystem. It invests in multinational pharmaceuticals as well as emerging biotechs with cutting-edge R&D; hospital chains and nursing care operators as well as providers of diagnostic and laboratory technologies; health insurers as well as healthcare software providers.

Industry Breakdown1
SectorLong % Short %Net %
Health Care 85.6 (2.6) 83.0
Industrials 0.6 - 0.6
Info Technology 0.3 - 0.3
Top 10 Positions3
StockCountryIndustry%
Takeda Pharma Co Japan Pharmaceuticals 3.8
SpeeDx Pty Ltd Australia Biotechnology 3.6
Sanofi SA France Pharmaceuticals 3.3
Bayer AG Germany Pharmaceuticals 2.9
Telix Pharmaceutical Australia Biotechnology 2.8
Kazia Therapeutics Australia Biotechnology 2.1
Zai Lab Ltd ADR China Biotechnology 2.0
Almirall SA Spain Pharmaceuticals 1.9
Quanterix Corp United States Life Sciences Tools & Services 1.8
CStone Pharma China Biotechnology 1.8
Total 25.9
Disposition of Assets2
Long %Short %Net %Currency%
Asia-Pacific 28.0 (0.3) 27.7 35.9
Australia 11.1 (0.3) 10.8 16.1
China 8.7 - 8.7 8.7
Hong Kong 0.7 - 0.7 0.7
Japan 6.3 - 6.3 4.5
New Zealand 0.9 - 0.9 0.9
Singapore 0.3 - 0.3 0.3
China Renminbi Off Shore - - - 4.8
Europe 23.4 - 23.4 35.3
Belgium 1.7 - 1.7 -
Denmark 1.1 - 1.1 1.1
France 4.0 - 4.0 -
Germany 9.5 - 9.5 -
Ireland 0.4 - 0.4 -
Netherlands 1.1 - 1.1 -
Spain 1.9 - 1.9 -
Sweden 0.8 - 0.8 0.8
Switzerland 1.3 - 1.3 1.3
United Kingdom 1.7 - 1.7 5.1
Euro - - - 27.0
North America 35.2 (2.4) 32.8 28.8
Canada 0.7 - 0.7 0.7
United States 34.5 (2.4) 32.2 28.1
Sub-Total 86.6 (2.6) 83.9 100.0
Cash 13.4 - 16.1 -
Total 100.0 - 100.0 100.0
Long - 91 stocks, 2 options Short - 2 swaps
Top 10 Positions3
StockCountryIndustry%
Takeda Pharma Co Japan Pharmaceuticals 3.8
SpeeDx Pty Ltd Australia Biotechnology 3.6
Sanofi SA France Pharmaceuticals 3.3
Bayer AG Germany Pharmaceuticals 2.9
Telix Pharmaceutical Australia Biotechnology 2.8
Kazia Therapeutics Australia Biotechnology 2.1
Zai Lab Ltd ADR China Biotechnology 2.0
Almirall SA Spain Pharmaceuticals 1.9
Quanterix Corp United States Life Sciences Tools & Services 1.8
CStone Pharma China Biotechnology 1.8
Total 25.9
All data as at [31 December 2020] .
  1. “Long %” represents the Fund’s effective exposures to the relevant sectors as a percentage of the Fund’s NAV, taking into account direct stock holdings and long derivative positions (stocks and indices). “Net %” represents the Fund’s net exposures to the relevant sectors as a percentage of the Fund’s NAV, taking into account direct stock holdings and both long and short derivative positions (stocks and indices).
  2. “Long %” represents the Fund’s effective exposures to the relevant regions as a percentage of NAV through stock holdings and long derivatives (stocks and indices). “Net %” represents the Fund’s net exposures to the relevant regions as a percentage of NAV through stock holdings and both long and short derivatives (stocks and indices). “Currency %” represents the Fund’s effective exposures to the relevant currencies as a percentage of NAV through stock holdings, cash and the use of derivatives.
  3. The “Top 10 Positions” table shows the Fund’s top 10 long stock positions as a percentage of the Fund's NAV, taking into account direct stock holdings and long derivative positions.